pharmacogenetics and personalized medicine in pancreatic cancer

Pharmacogenetics/genomics and personalized medicine.

Despite the marked advances in drug therapy, some patients do not respond favorably or suffer severe adverse drug effects. Pharmacogenetic studies have shown that polymorphisms of drug metabolizing enzymes, transporters and receptors contribute to variable drug response. Owing to the complexity of drug actions, a broader genomics approach aims at finding new drug targets and optimizing therapy ...

Pharmacogenetics, Personalized Medicine, and Race

Metabolic pathways — the chains of chemical reactions that occur in each cell in the body — are affected by a wide range of DNA mutations, including single nucleotide polymorphisms (SNPs); gene deletions, duplications, and insertions; mutations in the regulatory elements of genes; and variations in gene copy number. The identification of gene variants (alleles) that influence drug metabolism is...

Pharmacogenetics and Pharmacogenomics of Colorectal Cancer: Moving Towards Personalized Medicine

Pharmacogenetics in pancreatic cancer.

Pancreatic cancer is an aggressive malignancy with a poor overall survival rate. Given advances in pharmacogenomics, numerous gene mutations have been identified that could be potential targets for drug development. Therefore, future research strategies may identify prognostic and predictive markers aiming to improve outcome by maximizing efficacy whilst lowering toxicity. In this commentary, w...

Personalized RNA Medicine for Pancreatic Cancer.

Purpose: Since drug responses vary between patients, it is crucial to develop pre-clinical or co-clinical strategies that forecast patient response. In this study, we tested whether RNA-based therapeutics were suitable for personalized medicine by using patient-derived-organoid (PDO) and patient-derived-xenograft (PDX) models.Experimental Design: We performed microRNA (miRNA) profiling of PDX s...

Pharmacogenetics in breast cancer: steps toward personalized medicine in breast cancer management

There is wide individual variability in the pharmacokinetics, pharmacodynamics, and tolerance to anticancer drugs within the same ethnic group and even greater variability among different ethnicities. Pharmacogenomics (PG) has the potential to provide personalized therapy based on individual genetic variability in an effort to maximize efficacy and reduce adverse effects. The benefits of PG inc...